FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely neurology, endocrinology, and can be used for diagnosing cognitive disorders in patients with type 1 and type 2 diabetes mellitus (DM). Perform magnetic resonance perfusion. Total cerebral blood flow is determined. If level is 56 ml / 100 g / min or less with type 1 DM and 37.7 ml / 100 g / min or less in type 2 DM, cognitive dysfunction is diagnosed.
EFFECT: invention provides diagnosing cognitive disorders at early stages of development by evaluating cerebral blood flow.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PRECLINICAL DIAGNOSIS OF COGNITIVE IMPAIRMENT IN PATIENTS WITH TYPE 1 DIABETES MELLITUS | 2021 |
|
RU2772714C1 |
| DIAGNOSTIC TECHNIQUE FOR COGNITIVE DYSFUNCTION IN PATIENTS WITH TYPE 1 DIABETES MELLITUS BY PROTON MAGNETIC RESONANCE SPECTROSCOPY | 2018 |
|
RU2705911C1 |
| METHOD OF EARLY DIAGNOSTICS OF COGNITIVE DISORDERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | 2015 |
|
RU2620550C1 |
| DIAGNOSTIC METHOD OF SEVERITY DEGREE OF DIABETIC ENCEPHALOPATHY WITH CHILDREN AND TEENAGERS | 2008 |
|
RU2368905C1 |
| METHOD OF EARLY DIAGNOSIS OF COGNITIVE IMPAIRMENTS IN YOUNG AND MIDDLE-AGED PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH MINIMAL NEUROLOGICAL SYMPTOMS | 2021 |
|
RU2790236C1 |
| METHOD OF EARLY DETECTION OF DIABETICAL ENCEPHALOPATHY IN CHILDREN | 2008 |
|
RU2389027C2 |
| METHOD OF REMOTE PREDICTION OF NEORUCOGNITIVE FUNCTION FOR PATIENTS WHO HAVE STOOD CORONARY SHUNTING | 2005 |
|
RU2307591C2 |
| THERAPY OF PATIENTS SUFFERING FROM PANCREATIC DIABETES COMBINED WITH CENTRAL NERVOUS SYSTEM DAMAGE | 2008 |
|
RU2360676C1 |
| METHOD FOR PREDICTING PROGRESSION OF VASCULAR MODERATE COGNITIVE IMPAIRMENT | 2023 |
|
RU2816620C1 |
| METHOD FOR ASSESSING THE RATE OF CEREBRAL BLOOD FLOW IN NEURONAL ACTIVATION ZONES | 2018 |
|
RU2702587C1 |
